Ava Vila-Leahey
YOU?
Author Swipe
View article: MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model
MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model Open
Background Novel treatments are needed for epithelial ovarian cancer, the most lethal gynecologic malignancy due to late diagnosis, resistance to treatment, and high relapse rate. Immunotherapies such as checkpoint inhibitors (i.e, anti-PD…
View article: 1336 DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens
1336 DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens Open
Background For peptide-based cancer vaccines, successful eradication of tumors relies on the effective and persistent delivery of antigenic peptides to antigen presenting cells (APCs) to prime potent antigen-specific, cytotoxic T cells. Pe…
View article: Generation of highly activated, antigen-specific tumor-infiltrating CD8 <sup>+</sup> T cells induced by a novel T cell-targeted immunotherapy
Generation of highly activated, antigen-specific tumor-infiltrating CD8 <sup>+</sup> T cells induced by a novel T cell-targeted immunotherapy Open
The induction of tumor-targeted, cytotoxic T lymphocytes has been recognized as a key component to successful immunotherapy. DPX-based treatment was previously shown to effectively recruit activated CD8+ T cells to the tumor. He…
View article: Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response
Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response Open
These data demonstrate an important role for B cells in the enhanced antitumor immune response that occurs in response to ranitidine treatment. Our findings are consistent with a model, whereby ranitidine reduces tumor-associated immune su…
View article: Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice
Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice Open
Histamine receptor 2 (H2) antagonists are widely used clinically for the control of gastrointestinal symptoms, but also impact immune function. They have been reported to reduce tumor growth in established colon and lung cancer models. His…
View article: The impact of ranitidine on monocyte responses in the context of solid tumors
The impact of ranitidine on monocyte responses in the context of solid tumors Open
Monocytes and myeloid derived suppressor cells (MDSC) have been implicated on the regulation of tumor growth. Histamine is also important for regulating MDSC responses. Oral administration of the H2 receptor antagonist ranitidine can inhib…